Stay Updated with the Latest Merck KGaA MRK.DE News in Real Time
Find MRK.DE news now at Meyka AI. Stay informed with the latest Merck KGaA stocks updates, including price news, market analysis, and expert insights.
Moderna and Merck’s Melanoma Vaccine Jumps Stocks on Phase 3 Win
Moderna and Merck’s personalized mRNA cancer vaccine succeeded in Phase 3 melanoma trials, reducing disease recurrence. MRNA jumped 8.9% and MRK rose 2.4% on the announcement.
Moderna Tumbles 23.5% After 177% Surge on Cancer Vaccine Win, August 21
Moderna stock fell 23.5% to $133.32 on August 21 after surging 177% the prior day on its cancer vaccine breakthrough with Merck. RSI hit record 92.21, signaling extreme overbought conditions.
Moderna Soars 122% on Melanoma Vaccine Breakthrough, August 21
Moderna stock jumps 122% after announcing its personalized mRNA melanoma vaccine met Phase 3 trial goals. The vaccine reduced cancer recurrence and spread when combined with Merck’s Keytruda.
Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12% on August 20
Moderna jumps 177% and Merck rises 12% after their mRNA cancer vaccine meets Phase 3 endpoints for melanoma. The combo reduced cancer recurrence and spread in over 1,100 patients.
Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20
Moderna stock jumped 177% after its melanoma vaccine met Phase 3 trial endpoints. The personalized mRNA therapy showed significant improvements over standard treatment in over 1,100 patients.
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.
Moderna Soars 177% After Melanoma Vaccine Clears Late-Stage Trial on August 19
Moderna jumps 177% and Merck gains 12% after their personalized mRNA cancer vaccine met key goals in a Phase 3 melanoma trial, the first positive late-stage result for an mRNA cancer therapy.
Moderna Soars 177% on Melanoma Vaccine Win; Merck Gains 12%
Moderna jumped 177% and Merck rose 12% after announcing the first Phase 3 win for an mRNA cancer vaccine. The personalized treatment reduced melanoma recurrence risk significantly.
TGA Warns GLP-1 Drugs Like Ozempic Linked to Rare Eye Blindness July 25
Australia’s TGA warns GLP-1 drugs like Ozempic may cause NAION, a rare eye disorder leading to blindness. 36 cases reported. No treatment available. Patients urged to seek urgent medical attention if vision changes occur.